{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:32:02Z","timestamp":1760297522971},"reference-count":34,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1253\/circj.69.1099","type":"journal-article","created":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T05:56:23Z","timestamp":1124949383000},"page":"1099-1104","source":"Crossref","is-referenced-by-count":12,"title":["Exercise After Heparin Administration"],"prefix":"10.1253","volume":"69","author":[{"given":"Yasuhiro","family":"Maejima","sequence":"first","affiliation":[{"name":"First Department of Integrated Medicine"},{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yasu","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Ueba","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemasa","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"},{"name":"Department of Cardiovascular & Renal Medicine, Saga University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kubo","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kakehashi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Omiya Medical Center, Jichi Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Kawakami","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneyasu","family":"Saito","sequence":"additional","affiliation":[{"name":"First Department of Integrated Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","first-page":"IV-1","volume":"84(Suppl 4)","year":"1991","unstructured":"1. Second European Consensus Document on Chronic Leg Ischemia. Circulation 1991; 84(Suppl 4): IV-1-IV-26.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schmieder FA, Comerota AJ. Intermittent claudication: Magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87: 3D-13D.","DOI":"10.1016\/S0002-9149(01)01671-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Antonicelli R, Sardina M, Scotti A, Bonizzoni E, Parciaroni E. Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication: Italian CAP Study Group. Am J Med 1999; 107: 234-239.","DOI":"10.1016\/S0002-9343(99)00224-7"},{"key":"4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/01.CIR.77.5.1022","volume":"77","year":"1988","unstructured":"4. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 1988; 77: 1022-1029.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999; 255: 80-87.","DOI":"10.1006\/bbrc.1999.0150"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Salbach PB, Bruckmann M, Turoverts O, Kreuzer J, Kubler W, Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000; 50: 221-226.","DOI":"10.1111\/j.1365-2125.2000.00246.x"},{"key":"7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/342440a0","volume":"342","year":"1989","unstructured":"7. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.","journal-title":"?Nature","ISSN":"http:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral arterial disease. Hum Gene Ther 1996; 7: 959-988.","DOI":"10.1089\/hum.1996.7.8-959"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by hepatocyte growth factor: Potential gene therapy for ischemic diseases. J Atheroscler Thromb 2000; 7: 71-76.","DOI":"10.5551\/jat1994.7.71"},{"key":"10","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","year":"2003","unstructured":"10. Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, et al; Representing the Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.","journal-title":"Ophthalmology","ISSN":"http:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999; 255: 80-87.","DOI":"10.1006\/bbrc.1999.0150"},{"key":"12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/01.CIR.102.5.565","volume":"102","year":"2000","unstructured":"12. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, et al. Adenovirus-mediated VEGF<sub>121<\/sub> gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102: 565-571.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsumoto K, Nakamura T. Emerging multipotent aspects hepatocyte growth factor. J Biochem 1996; 119: 591-600.","DOI":"10.1093\/oxfordjournals.jbchem.a021283"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995; 215: 483-488.","DOI":"10.1006\/bbrc.1995.2490"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: Additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067-1072.","DOI":"10.1097\/00004872-199609000-00004"},{"key":"16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.CIR.97.4.381","volume":"97","year":"1998","unstructured":"16. Belle EV, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiographic effect of scatter factor\/hepatocyte growth factor: The case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-390.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rubin JS, Day RM, Breckenridge D, Atabey N, Tylor WG, Stahl SJ, et al. Dissociation of heparin sulfate and receptor binding domains of hepatocyte growth factor reveals that heparin sulfate-c-met interaction facilitates signaling. J Biol Chem 2001; 276: 32977-32983.","DOI":"10.1074\/jbc.M105486200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997; 30: 294-301.","DOI":"10.1097\/00005344-199709000-00004"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sato T, Tani Y, Murao S, Fujieda H, Sato H, Matsumoto M, et al. Focal enhancement of expression of c-Met\/hepatocyte growth factor receptor in the myocardium in human myocardial infarction. Cardiovasc Pathol 2001; 10: 235-240.","DOI":"10.1016\/S1054-8807(01)00079-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor\/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.","DOI":"10.1161\/01.CIR.95.11.2552"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yasuda S, Goto Y, Takaki H, Asaumi Y, Baba T, Miyazaki S, et al. Exercise-induced hepatocyte growth factor production in patients after acute myocardial infarction: Its relationship to exercise capacity and brain natriuretic peptide levels. Circ J 2004; 68: 304-307.","DOI":"10.1253\/circj.68.304"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gustafsson T, Knutsson A, Puntschart A, Kaijser L, Nordqvist AC, Sundberg CJ, et al. Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Pflugers Arch 2002; 444: 752-759.","DOI":"10.1007\/s00424-002-0845-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lloyd PG, Prior BM, Yang HT, Terjung RL. Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. Am J Physiol Heart Circ Physiol 2003; 284: H1668-H1678.","DOI":"10.1152\/ajpheart.00743.2002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Maejima Y, Ueba H, Kuroki M, Yasu T, Hashimoto S, Nabata A, et al. Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis 2003; 167: 89-95.","DOI":"10.1016\/S0021-9150(02)00384-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. B&ouml;ger RH, Bode-B&ouml;ger SM, Thiele W, Creutzig A, Alexander K, Fr&ouml;lich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-1344.","DOI":"10.1016\/S0735-1097(98)00375-1"},{"key":"26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.90.2.818","volume":"90","year":"1994","unstructured":"26. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease: The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994; 90: 818-822.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mehrabi MR, Serbecic N, Tamaddon F, Kaun C, Huber K, Pacher R, et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res 2002; 56: 214-224.","DOI":"10.1016\/S0008-6363(02)00591-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ischemia Cronica degli Arti Inferiori Study Group. Prostanoids for chronic critical leg ischemia: A randomized, controlled, open-label trial with prostaglandin E1: The ICAI Study Group. Ann Intern Med 1999; 130: 412-421.","DOI":"10.7326\/0003-4819-130-5-199903020-00005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for peripheral vascular diseases in man. J Pharm Pharmacol 1983; 35: 666-667.","DOI":"10.1111\/j.2042-7158.1983.tb02862.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997; 30: 294-301.","DOI":"10.1097\/00005344-199709000-00004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Xie X, Rivier AS, Zakrzewicz A, Bernimoulin M, Zeng XL, Wessel HP, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides: Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 2000; 275: 34818-34825.","DOI":"10.1074\/jbc.M001257200"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000; 47: 88-96.","DOI":"10.1136\/gut.47.1.88"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hata N, Matsumori A, Yokoyama S, Ohba T, Shinada T, Yoshida H, et al. Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Circ J 2004; 68: 645-649.","DOI":"10.1253\/circj.68.645"},{"key":"34","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/01.CIR.103.21.2591","volume":"103","year":"2001","unstructured":"34. Tateno S, Terai M, Niwa K, Jibiki T, Hamada H, Yasukawa K, et al. Alleviation of myocardial ischemia after Kawasaki Disease by heparin and exercise therapy. Circulation 2001; 103: 2591-2597.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/69\/9\/69_9_1099\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T06:57:21Z","timestamp":1552892241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/69\/9\/69_9_1099\/_article"}},"subtitle":["New Therapeutic Program for Patients With Non-Option Arteriosclerosis Obliterans"],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.69.1099","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}